Bolt Biotherapeutics
NASDAQ: BOLTSan Francisco, US · 8 known investors
Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer. The company focuses on cancer immunotherapeutics and myeloid biology to address unmet patient needs.
Founders & leadership
DE
Dr. Edgar G. EnglemanFounder
Investors · 8
Competitors · 2
by search overlapNorthwest Biotherapeutics20 shared keywordsNW Bio develops personalized dendritic cell-based cancer vaccines intended to treat a range of solid tumor cancers as an alternative to chemotherapy. Its clinical-stage products target cancers including glioblastoma, inoperable solid tumors, ovarian cancer, and prostate cancer.
Bioworld19 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Bolt Biotherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Bolt Biotherapeutics do?
- Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer. The company focuses on cancer immunotherapeutics and myeloid biology to address unmet patient needs.
- Who founded Bolt Biotherapeutics?
- Bolt Biotherapeutics was founded by Dr. Edgar G. Engleman.
- Who are Bolt Biotherapeutics's investors?
- Bolt Biotherapeutics's investors include Pfizer Venture Investments, RA Capital, Samsara BioCapital, Sofinnova Ventures, Vivo Capital, Nan Fung Life Sciences, Novo Holdings, Pivotal Life Sciences.
- Where is Bolt Biotherapeutics headquartered?
- Bolt Biotherapeutics is headquartered in San Francisco, US.